辛夷鼻炎丸联合布地奈德治疗变应性鼻炎的临床观察(1)
摘要：目的 分析辛夷鼻炎丸与布地奈德联合治疗变应性鼻炎的临床效果。方法 选取我院收治的112例变应性鼻炎患者，随机法分成对照组和观察组，各56例。对照组应用布地奈德治疗，观察组在此基础上加用辛夷鼻炎丸治疗，比较两组临床疗效、患者血清IgE水平、LTE4含量及用药不良反应。结果 观察组总有效率为85.71%，高于对照组的75.00%，差异有统计学意义(P<0.05);治疗4周观察组患者血清LTE4含量、IgE水平均低于对照组，差异有统计学意义(P<0.05);观察组不良反应发生率为5.36%，低于对照组的12.50%，但差异无统计学意义(P>0.05)。结论 辛夷鼻炎丸与布地奈德联合治疗变應性鼻炎的临床效果显著，可改善患者血清IgE水平、LTE4含量，安全性较好。
关键词：辛夷鼻炎丸;布地奈德;变应性鼻炎;IgE;LTE4
中图分类号：R765.21 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.03.052
, 百拇医药
文章编号：1006-1959(2019)03-0158-02
Abstract：Objective To analyze the clinical effect of Xinyi Biyan Wan combined with budesonide in the treatment of allergic rhinitis.Methods 112 patients with allergic rhinitis admitted to our hospital were randomly divided into control group and observation group， 56 cases each. The control group was treated with budesonide. The observation group was treated with Xinyi Biyan Wan. The clinical efficacy， serum IgE level， LTE4 content and adverse drug reactions were compared between the two groups.Results The total effective rate of the observation group was 85.71%， which was higher than that of the control group 75.00%，the difference was statistically significant (P<0.05).In the 4 weeks of treatment， the serum LTE4 content and IgE level of the observation group were lower than those of the control group，the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 5.36%， which was lower than that in the control group (12.50%)， but the difference was not statistically significant (P>0.05).Conclusion The clinical effect of Xinyi Biyan Wan combined with budesonide in the treatment of allergic rhinitis is significant， which can improve the serum IgE level and LTE4 content， and the safety is better.
, 百拇医药
Key words：Xinyi Biyan Wan;Budesonide;Allergic rhinitis;IgE;LTE4
变应性鼻炎(allergic rhinitis)病因复杂，属于非感染性疾病，易诱发鼻塞、流涕、喷嚏等症状，对患者生活质量造成影响。该病治疗棘手，目前无特效药物，常规治疗一般采用激素类药物控制病情，缓解临床症状，但激素类药物布地奈德并非对所有患者生效，因此需探讨更为有效的治疗方法[1]。辛夷鼻炎丸是一种中药制剂，可对鼻炎引起的鼻塞、流涕起到良好的缓解作用，与西药作用机制有所不同，可与激素类药物联合使用，改善治疗效果。为此，本研究探讨辛夷鼻炎丸联合布地奈德治疗变应性鼻炎的临床效果，现报道如下。
1 资料与方法
1.1一般资料 选择天津市滨海新区大港医院耳鼻喉科2015年12月～2018年2月收治的112例变应性鼻炎患者。纳入标准：①未应用过AR药物治疗者;②有个人、家族过敏疾病史者;③变应原皮肤试验结果为阳性者。排除标准：①精神疾病者;②合并严重器质病变者、肿瘤者;③无法配合治疗者。采取随机数表法将患者分成观察组与对照组，各56例。观察组中男37例，女19例，年龄21～49岁，平均年龄(32.70±7.71)岁，病程0.5～3.8年，平均病程(2.53±1.12)年;对照组男39例，女17例，年龄19～48岁，平均年龄(32.21±7.93)岁，病程0.4～4.0年，平均病程(2.47±1.21)年。两组患者性别、年龄等一般资料比较，差异无统计学意义(P>0.05)，具体可比性。, 百拇医药(邱亚双)
关键词：辛夷鼻炎丸;布地奈德;变应性鼻炎;IgE;LTE4
中图分类号：R765.21 文献标识码：A DOI：10.3969/j.issn.1006-1959.2019.03.052
, 百拇医药
文章编号：1006-1959(2019)03-0158-02
Abstract：Objective To analyze the clinical effect of Xinyi Biyan Wan combined with budesonide in the treatment of allergic rhinitis.Methods 112 patients with allergic rhinitis admitted to our hospital were randomly divided into control group and observation group， 56 cases each. The control group was treated with budesonide. The observation group was treated with Xinyi Biyan Wan. The clinical efficacy， serum IgE level， LTE4 content and adverse drug reactions were compared between the two groups.Results The total effective rate of the observation group was 85.71%， which was higher than that of the control group 75.00%，the difference was statistically significant (P<0.05).In the 4 weeks of treatment， the serum LTE4 content and IgE level of the observation group were lower than those of the control group，the difference was statistically significant (P<0.05). The incidence of adverse reactions in the observation group was 5.36%， which was lower than that in the control group (12.50%)， but the difference was not statistically significant (P>0.05).Conclusion The clinical effect of Xinyi Biyan Wan combined with budesonide in the treatment of allergic rhinitis is significant， which can improve the serum IgE level and LTE4 content， and the safety is better.
, 百拇医药
Key words：Xinyi Biyan Wan;Budesonide;Allergic rhinitis;IgE;LTE4
变应性鼻炎(allergic rhinitis)病因复杂，属于非感染性疾病，易诱发鼻塞、流涕、喷嚏等症状，对患者生活质量造成影响。该病治疗棘手，目前无特效药物，常规治疗一般采用激素类药物控制病情，缓解临床症状，但激素类药物布地奈德并非对所有患者生效，因此需探讨更为有效的治疗方法[1]。辛夷鼻炎丸是一种中药制剂，可对鼻炎引起的鼻塞、流涕起到良好的缓解作用，与西药作用机制有所不同，可与激素类药物联合使用，改善治疗效果。为此，本研究探讨辛夷鼻炎丸联合布地奈德治疗变应性鼻炎的临床效果，现报道如下。
1 资料与方法
1.1一般资料 选择天津市滨海新区大港医院耳鼻喉科2015年12月～2018年2月收治的112例变应性鼻炎患者。纳入标准：①未应用过AR药物治疗者;②有个人、家族过敏疾病史者;③变应原皮肤试验结果为阳性者。排除标准：①精神疾病者;②合并严重器质病变者、肿瘤者;③无法配合治疗者。采取随机数表法将患者分成观察组与对照组，各56例。观察组中男37例，女19例，年龄21～49岁，平均年龄(32.70±7.71)岁，病程0.5～3.8年，平均病程(2.53±1.12)年;对照组男39例，女17例，年龄19～48岁，平均年龄(32.21±7.93)岁，病程0.4～4.0年，平均病程(2.47±1.21)年。两组患者性别、年龄等一般资料比较，差异无统计学意义(P>0.05)，具体可比性。, 百拇医药(邱亚双)